Protoporphyria Clinical Trials

Find Protoporphyria Clinical Trials Near You

A Phase 2b/3, Quadruple-Blinded, Randomized, Placebo-Controlled Study of PORT-77 Administered Orally to Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria and an Open-Label Extension

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY

PATHWAY is a Phase 2b/3 clinical study with an Open-Label Extension (OLE). It tests PORT-77 in patients with EPP, EPP2, and XLP. The study has three parts: Part 1: Phase 2b * Find the right dose of PORT-77 to lower PPIX levels in the blood * Test if PORT-77 lowers PPIX levels better than placebo * Check the safety of each dose Part 2: Phase 3 * Test if PORT-77 lowers PPIX levels better than placebo * Test if PORT-77 increases the amount of time patients spend in sunlight each day without pain compared to placebo * Check the safety of PORT-77 Part 3: Open-Label Extension (OLE) * Test the long-term effect of PORT-77 on PPIX levels and time in sun * Monitor long-term safety

Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Healthy Volunteers: f
View:

• Aged 12 years or older.

• Clinical history of EPP, XLP, or EPP2 supported by genetic confirmation or historical laboratory test results

• History of consistent, non-painful prodrome within approximately 45 minutes of sunlight exposure and prior to phototoxic attacks

• Demonstrates ≥85% compliance with daily symptom diary during run-in period.

• Body weight or BMI at Screening as follows:

‣ For participants aged 12 to \<18 years: body weight ≥32 kg

⁃ For participants aged ≥18 years: BMI ≥18.5 kg/m2

• AST and ALT \<3 × ULN and total bilirubin \<2 × ULN (unless documented Gilbert syndrome) at Screening

• Willing and able to provide informed consent and/or assent for the study.

• Willing and able to comply with study visits, study procedures, and contraception guidance

• Intends to remain in the same approximate geographic latitude for the duration of the placebo-controlled period, with no more than 14 days spent outside this region.

Locations
United States
California
Investigative Site
RECRUITING
Huntington Beach
Ohio
Investigative Site
RECRUITING
Cincinnati
Contact Information
Primary
Portal Therapeutics, Inc.
Portal.clinical.trials@gondolabio.com
877-660-6479
Time Frame
Start Date: 2026-09
Estimated Completion Date: 2029-09
Participants
Target number of participants: 225
Treatments
Experimental: Phase 2b (Treatment Group 1)
PORT-77 Dose 1
Experimental: Phase 2b (Treatment Group 2)
PORT-77 Dose 2
Placebo_comparator: Phase 2b (Treatment Group 3)
Placebo
Experimental: Phase 3 (Treatment Group 1)
PORT-77
Placebo_comparator: Phase 3 (Treatment Group 2)
Placebo
Experimental: Phase 3 (Open-Label Extension)
PORT-77
Sponsors
Leads: Portal Therapeutics, Inc.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

We couldn't find any related articles check for more on the main search page.